SCHEMBL2886835

SCHEMBL2886835

CCOC(=O)CN(Cc1ccc(OC)cc1OC)Cc1nc(-c2cccc(OC)c2)sc1C(=O)OCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 1/20 0.44
TRPM8 Q7Z2W7 3/20 0.43
ALDH1A1 P00352 4/20 0.42
HPGD P15428 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 2/20 0.42
HSD17B10 Q99714 2/20 0.42
USP2 O75604 1/20 0.42
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
MAPT P10636 3/20 0.41
CDC7 O00311 4/20 0.40
DBF4 Q9UBU7 4/20 0.40
POLB P06746 1/20 0.40
DHODH Q02127 1/20 0.40
HTT P42858 1/20 0.39
TP53 P04637 1/20 0.39
LMNA P02545 1/20 0.39
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2883109 0.94 CDC7 (0.48) PTPN11TRPM8ALDH1A1SMN1; SMN2KDM4E
SCHEMBL2883557 0.92 PTPN11 (0.47) PTPN11TRPM8ALDH1A1HPGDSMN1; SMN2
SCHEMBL2881201 0.92 PTPN11 (0.52) PTPN11TRPM8ALDH1A1HPGDSMN1; SMN2
SCHEMBL2886405 0.92 PTPN11 (0.45) PTPN11TRPM8ALDH1A1HPGDKDM4E
SCHEMBL2887022 0.91 PTPN11 (0.46) PTPN11TRPM8ALDH1A1HPGDKDM4E
SCHEMBL2881257 0.89 TRPM8 (0.49) PTPN11TRPM8HPGDSMN1; SMN2KDM4E
SCHEMBL2881281 0.89 PTPN11 (0.43) PTPN11TRPM8ALDH1A1KDM4EMEN1
SCHEMBL2882201 0.88 PTPN11 (0.40) PTPN11ALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL2888316 0.88 PTPN11 (0.46) PTPN11TRPM8ALDH1A1KDM4EMEN1
SCHEMBL2886624 0.87 PTPN11 (0.48) PTPN11TRPM8ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
EP-2016078-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2009-01-21 EP disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed
WO-2007115315-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 PTPN11 1671/4885TRPM8 3499/4885ALDH1A1 1047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.